Clinical Trials · NCT00835211

Desmopressin Acetate 0.2 mg Tablets, Fasting

CompletedPhase 1Desmopressin (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Teva Pharmaceuticals USA
Enrollment
48
Start date
Jul 2003
Locations
1 site, Canada
Primary endpoint
Cmax - Maximum Observed Concentration
View Desmopressin compound reference